Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 11/20 | 0.57 |
| ▸ | DRD2 | P14416 | 9/20 | 0.57 |
| ▸ | DRD5 | P21918 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627010 | 0.96 | DRD1 (0.55) | DRD1DRD2DRD5DRD3ADRA1D | |
| SCHEMBL13430580 | 0.96 | DRD1 (0.55) | DRD1DRD2DRD5DRD3ADRA1D | |
| SCHEMBL16627000 | 0.86 | DRD1 (0.57) | DRD1DRD2DRD5DRD3ADRA1D | |
| SCHEMBL16627001 | 0.83 | DRD1 (0.54) | DRD1DRD2DRD5DRD3ADRA1D | |
| SCHEMBL16625809 | 0.83 | DRD1 (0.46) | DRD1DRD2DRD5DRD3ADRA1D | |
| SCHEMBL16627026 | 0.82 | DRD1 (0.53) | DRD1DRD2DRD5DRD3ADRA1A | |
| SCHEMBL16627024 | 0.82 | DRD1 (0.53) | DRD1DRD2DRD5DRD3ADRA1A | |
| SCHEMBL16627029 | 0.82 | DRD1 (0.53) | DRD1DRD2DRD5DRD3ADRA1D | |
| SCHEMBL11753989 | 0.81 | RAD52 (0.57) | DRD1DRD2DRD5DRD3 | |
| SCHEMBL11750868 | 0.81 | RAD52 (0.57) | DRD1DRD2DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856251-B2 | Substituted berbines and processes for their synthesis | MALLINCKRODT LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160347747-A1 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | MALLINCKRODT INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347747-A1 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | MALLINCKRODT INC. | 2016-12-01 | — | — | US | disclosed |
| US-9458109-B2 | Substituted berbines and processes for their synthesis | MALLINCKRODT LLC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458109-B2 | Substituted berbines and processes for their synthesis | MALLINCKRODT LLC (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2010028004-A2 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | MALLINCKRODT INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056789-A1 | Substituted Berbines and Processes for their Synthesis | MALLINCKRODT INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056789-A1 | Substituted Berbines and Processes for their Synthesis | MALLINCKRODT INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347747-A1 | SUBSTITUTED BERBINES AND PROCESSES FOR THEIR SYNTHESIS | TYMS, BLVRB, DHPS | DRD1 1322/4885DRD2 1069/4885DRD5 1340/4885 |
| US-20100056789-A1 | Substituted Berbines and Processes for their Synthesis | TYMS, BLVRB, DHPS | DRD1 1322/4885DRD2 1069/4885DRD5 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.